TERAPIA CELULAR Y MEDICINA REGENERATIVA
Institut d'Investigació Biomédica de Bellvitge
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Institut d'Investigació Biomédica de Bellvitge (4)
2024
-
Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms
British Journal of Haematology
2021
-
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (Leukemia, (2021), 35, 7, (2119-2124), 10.1038/s41375-021-01125-4)
Leukemia
-
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Leukemia
-
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
Nature Communications, Vol. 12, Núm. 1